00809 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED * 有關以公開招標方式訂立的EPC合約的須予披露交易 以公開招標方式訂立EPC合約 茲提述本公司日期為二零二五年五月二十三日有關就EPC合約開始公開招標的公告。 以公開招標方式訂立EPC合約 茲提述本公司日期為二零二五年五月二十三日有關就EPC合約開始公開招標的公告。 誠如本公司日期為二零二五年五月二十三日的公告所披露，長春大合已就EPC合約發出招 標公告邀請投標者，該招標已於二零二五年五月二十六日開始。由於並無足夠的投標者 參與該招標，長春大合已分別於二零二五年六月三日（已於二零二五年六月二十三日截 止，無中標者）及二零二五年六月二十四日發出另外兩份招標公告，邀請投標者競投EPC 合約。於日期為二零二五年六月二十四日的招標公告中，為激勵承包商參加招標，已加 入提供的獎金的條款以獎勵提前竣工鍋爐 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 00809 涉及根據特別授權發行代價股份之 供應商債務重組安排 延遲寄發通函 茲提述大成生化科技集團有限公司（「本公司」）日期為二零二五年七月八日之公告（「該公 告」），內容有關涉及根據特別授權發行代價股份之供應商債務重組安排。除文義另有所 指外，本公告所用詞彙與該公告所界定者具有相同涵義。 由於需要額外時間編製及落實將納入通函（「通函」）的若干資料，誠如該公告所述，其應 載有（其中包括）(i)股份購買協議及其項下擬進行交易（包括重新收購及授出發行代價股份 之特別授權）之進一步資料；(ii)股東特別大會通告；及(iii)上市規則規定須予披露之其他 資料，預期通函寄發予股東的日期將延遲至二零二五年八月二十二日或之前。 承董事會命 大成生化科技集團有限公司 主席 王成 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED * 香港，二零二五年七月三十一日 於本公告 ...

格隆汇6月9日丨大成生化科技(00809.HK)公告，为促成供应商债务重组安排，相关供应商近期已专为供 应商债务重组安排设立供应商中国合伙企业。所有供应商中国合伙企业均以相同方式设立，因此所有相 关供应商参照集团结欠彼等的应付款项金额享有供应商债务重组安排项下的同等权利。 于2025年6月9日，(i)各供应商中国合伙企业(作为初始债权人及认购人)；(ii)世纪大成(作为债务人及发 行人)；(iii)公司全资附属公司及世纪大成直接股东大成生化科技集团有限公司("大成香港")订立各份债 转股协议。根据债转股协议，各供应商中国合伙企业将动用各供应商债务金额(合共人民币461.1百万元) 认购世纪大成新增注册资本，于完成后，该等资本应视为已缴足注册资本，合共占世纪大成约28.98% 股权。 债转股协议完成须待集团取得所有监管同意及授权，包括但不限于商务部主管部门所要求的批准或备案 后，方告作实。债转股协议完成后，世纪大成将由供应商中国合伙企业合共持有约28.98%，及由大成 香港持有约71.02%。世纪大成将仍为公司附属公司。债转股协议已包含禁售条款，据此供应商中国合 伙企业所持世纪大成任何股权仅可为供应商债务重组安 ...

诚如本公司截至2024年12月31日止年度的年报所披露，长春大合的生产设施于2024年全年保持正常营 运，并于年内为本集团贡献大量收入。尽管长春大合对本集团有重大财务贡献，惟自其生产厂区成立以 来超过20年间，长春大合一直使用中温/次高压锅炉及配套发电机组。鉴于中国广泛使用更具成本效益 的高温/高压及超高温/超高压锅炉，并考虑到本集团整体的可持续发展，长春大合有必要对其生产厂区 的锅炉设施进行翻修，并对锅炉机组进行系统升级，以降低成本并提升市场竞争力。由于本集团主要于 中国从事生产及销售玉米提炼产品及以玉米为原料的生化产品，本集团并无进行同类及类似规模翻修项 目的相关资质及能力。通过订立EPC合约，本集团可将锅炉翻修项目外判予合适的EPC承包商，从而减 少不必要的行政成本，并通过公平竞争选择优质供应商。 智通财经APP讯，大成生化科技(00809)发布公告，该公司已议决重新启动长春大合的锅炉翻修项目，并 拟通过与合适的EPC 承包商签订EPC合约，以(其中包括)对长春大合的锅炉设施进行翻修。由于本公司 的控股股东最终由吉林省国资委控制，本集团须通过公开招标方式为锅炉翻修项目遴选合适的EPC承包 商，且本公司须 ...

Core Viewpoint - The company, Dachen Biochemical Technology (00809), is actively engaging in strategic partnerships to enhance its capabilities in synthetic biology, particularly in the context of the Changchun Economic and Technological Development Zone initiative [1][2]. Group 1: Strategic Partnerships - Dachen Biochemical Technology's subsidiary, Changchun Hongcheng Biochemical Materials Technology Development Co., Ltd., has entered into a strategic cooperation framework agreement with Hefei Hechen Biotechnology Co., Ltd. to leverage their respective strengths in synthetic biology [2]. - The collaboration aims to focus on the industrial application of synthetic biology in the amino acid sector, combining Dachen's expertise in process optimization and cost control with Hefei Hechen's strengths in gene design and metabolic pathway optimization [2]. Group 2: Industry Development Initiatives - The Changchun Economic and Technological Development Zone is establishing a synthetic biology industry innovation development pilot area, with the goal of promoting high-quality industrial development in Northeast China [1]. - A key aspect of the initiative includes the signing of the Changxing Oasis Sub-Fund, which has been established with a capital of RMB 50 million, focusing on applications of synthetic biology in biomanufacturing, agricultural technology, and green energy [1]. Group 3: Research and Development Facilities - The strategic cooperation will utilize the research center and pilot facilities located at the company's Xinglongshan production base, which includes approximately 10,000 square meters of factory space and four research and development centers [2]. - The pilot platform's inauguration during the conference signifies a crucial step in bridging the gap between technological achievements and industrial application, particularly in biobased chemicals and medical materials [2]. Group 4: Current Operations Status - As of the announcement date, the company's Xinglongshan production base remains suspended from operations [3].

Group 1 - The core viewpoint of the news is that Dachen Biochemical Technology (00809.HK) has entered into a strategic cooperation framework agreement with Hefei Hechen Biotechnology Co., focusing on the development of synthetic biology applications in the amino acid sector [1][2] - The strategic cooperation aims to leverage the strengths of both parties in synthetic biology, combining Dachen's experience in technology scaling, process optimization, and cost control with Hefei Hechen's expertise in gene design and metabolic pathway optimization [1][2] - A pilot platform for synthetic biology will be established at Dachen's Xinglongshan production base, which includes approximately 10,000 square meters of research and development facilities, supporting the industrialization of bio-based chemicals and medical materials [2] Group 2 - The unveiling of the pilot platform during the conference signifies a crucial step in bridging the gap between technological achievements and industrial application, facilitating breakthroughs in the bio-based chemical and medical materials sectors [2] - Hefei Hechen is focused on integrating synthetic biology with advanced delivery technologies, developing bio-based chemicals, specialty amino acids, and high-value active ingredients, as well as offering solutions for beauty products and functional food applications [2]

Financial Performance - The total revenue for the year ended December 31, 2024, was HKD 2,001,095,000, representing a 45.5% increase from HKD 1,373,938,000 in 2023[3] - Gross profit for the same period was HKD 190,972,000, compared to HKD 43,637,000 in 2023, indicating a significant improvement in profitability[3] - The net profit attributable to the company's owners for 2024 was HKD 769,598,000, down 81.8% from HKD 4,224,593,000 in 2023[5] - The company reported a pre-tax profit from continuing operations of HKD 745,619,000, a decrease of 80.1% from HKD 3,701,045,000 in the previous year[3] - Total comprehensive income for the year was HKD 358,324,000, a decline of 89.8% compared to HKD 3,508,029,000 in 2023[5] - Revenue from continuing operations for 2024 reached HKD 2,001,095,000, a 45.5% increase from HKD 1,373,938,000 in 2023[34] - The total profit before tax for the fiscal year was HKD 3,701,045,000, with the amino acids segment showing a significant improvement in performance compared to the previous year[31] - The company reported a total profit for the year of HKD 769,598,000, which includes a profit from discontinued operations of HKD 481,466,000[31] Assets and Liabilities - The company’s total assets decreased to HKD 4,442,182,000 in 2024 from HKD 5,209,096,000 in 2023, reflecting a reduction of 14.7%[6] - Current liabilities amounted to HKD 6,486,145,000, down from HKD 8,395,603,000 in 2023, indicating a 22.8% decrease[6] - As of December 31, 2024, the group recorded a net current liability of approximately HKD 4,386,400,000, down from HKD 7,426,100,000 as of December 31, 2023[10] - The group's net liabilities were approximately HKD 1,954,400,000 as of December 31, 2024, compared to HKD 4,036,900,000 in the previous year[10] - The company’s total liabilities decreased to HKD 2,658,768,000 in 2024 from HKD 3,571,683,000 in 2023, a reduction of 25.5%[52] Cash Flow and Financial Management - The company’s cash and bank balances were HKD 85,470,000, slightly down from HKD 88,246,000 in 2023[6] - The group plans to enhance operational cash flow by maximizing production capacity in its amino acid business and expects to launch a series of high-value products to increase sales[11] - The group is implementing measures to reduce operating costs and develop new businesses to strengthen cash flow during market volatility[11] - The group anticipates that its amino acid business will continue to generate sufficient cash inflow in 2025[11] - The financial costs for continuing operations decreased to HKD 323,402,000 in 2024 from HKD 750,351,000 in 2023, indicating improved financial management[38] Operational Highlights - The company has not reported any significant changes in its main business operations, which focus on the production and sale of corn-refined products and biochemical products[8] - The group completed the sale of Changchun Dacheng Industrial Group, improving its financial condition by eliminating liabilities associated with the sold group[10] - The group recognized a one-time gain from debt restructuring of approximately HKD 4,284,800,000, significantly impacting the financial results for the year[39] - The group reported a significant one-time gain of approximately HKD 1,962,100,000 from the sale of subsidiaries, which are no longer consolidated in the financial statements[69] Market and Product Development - The company is exploring new strategies for market expansion and product development, although specific details were not disclosed in the report[8] - The amino acid segment's revenue increased by approximately 50.2% to HKD 1,736,900,000, compared to HKD 1,156,700,000 in the previous year, with a sales volume of 280,000 tons[71] - The group plans to redesign the boiler facility renovation project to reduce amino acid production costs and enhance competitiveness[68] Shareholder Information - The company does not recommend any dividend distribution for the current year, consistent with 2023[42] - The company issued 14,535,514,629 shares of convertible preferred stock to Jilin Liheng and 2,732,235,940 shares to Jilin Yuanheng, with a conversion ratio of one preferred share to one common share[55] - The total value of the convertible preferred stock subscription amounts to approximately HKD 1,726,775,056.97, equivalent to RMB 1,580,000,000[56] - The company repurchased 31,666,000 shares under the share buyback authorization, which is 10% of the total shares issued as of the special general meeting[57] Employee and Operational Metrics - The group employed approximately 1,567 full-time employees as of December 31, 2024, a decrease from 2,154 in 2023[106] - Employee costs from continuing operations amounted to approximately HKD 107.97 million, down from HKD 115.04 million in 2023[106] Compliance and Reporting - The adoption of new and revised Hong Kong Financial Reporting Standards has not had a significant impact on the consolidated financial statements[16] - The company's financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards, presenting a true and fair view of its financial position as of December 31, 2024[61] - The auditor confirmed that the figures in the announcement align with the group's consolidated financial statements for the year[115]

GLOBAL Bio-Chem Technology Group Company Limited 大 成 生 化 科 技 集 團 有 限 公 司 * 股份代號：00809 中 期 報 目錄 | --- | --- | |------------------------------|-------| | | | | | | | 釋義 2 | | | 公司資料 6 | | | 致股東簡報 7 | | | 管理層討論及分析 9 | | | 其他資料的披露 21 | | | 簡明綜合財務報表 | | | 簡明綜合損益及其他全面收益表 | 28 | | 簡明綜合財務狀況表 30 | | | 簡明綜合權益變動表 32 | | | 簡明綜合現金流量表 33 | | | 簡明綜合財務報表附註 35 | | C017167 | --- | --- | --- | |--------------------------|-------|-------------------------------------------------------------------------------------------------- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 *僅供識別 — 1 — GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大 成 生 化 科 技 集 團 有 限 公 司 * （於開曼群島註冊成立的有限公司） （股份代號：00809） 截至2024年6月30日止六個月 中期業績公告 大成生化科技集團有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此公佈本公 司及其附屬公司（統稱「本集團」）截至2024年6月30日止六個月（「本期間」）的未經 審核綜合中期業績。 簡明綜合損益及其他全面收益表 截至2024年6月30日止六個月 截至6月30日止六個月 | --- | --- | --- | --- | |----------------------------------------------------------------------------------------|----------| ...

Financial Performance - Total revenue for 2023 was 715 million, a decrease from 811 million in 2022, representing a decline of approximately 11.8%[67]. - The net asset value of the indirect major shareholder, Nongtou, was approximately RMB 2,010.7 million as of December 31, 2023, down from RMB 2,105.5 million in 2022, indicating a decrease of about 4.5%[74]. - The company plans to repay the total transferred loans amounting to RMB 1,580 million to Nongtou by January 30, 2024, as part of its debt restructuring agreement[89]. - The company has successfully transferred a total of RMB 1,580 million, including net proceeds from the convertible preferred shares subscription, to Nongtou for loan repayment[89]. - The company anticipates that the unpaid amount for the repurchase loans will be settled in 2024 and/or 2025[90]. - The company completed the issuance of convertible preferred shares on January 4, 2024, raising net proceeds of approximately HKD 1,716,800,000, significantly improving the group's financial position[93]. Operational Efficiency - The inventory turnover days have significantly decreased to approximately 20 days from 235 days as of December 31, 2022, indicating improved operational efficiency[4]. - The group plans to upgrade production facilities in Changchun to reduce production costs and aims to launch various new amino acid products in 2024, which is expected to provide stable cash inflows[13]. - The company is focusing on operational cash flow monitoring and partial recovery of production operations[91]. - Efforts are being made to upgrade production facilities to improve production efficiency and product mix in response to market changes[158]. Workforce Management - The total employee cost from continuing operations for the year was approximately HKD 115.04 million, down from HKD 196.53 million in 2022, indicating a reduction in workforce expenses[15]. - The company has reduced its full-time employees to approximately 2,154 from 3,500 in 2022, reflecting a strategic adjustment in workforce management[15]. - The company emphasizes the importance of employee selection, training, and evaluation to align performance with strategic goals[186]. Corporate Governance - The board emphasizes the importance of corporate governance to enhance confidence among shareholders and stakeholders, focusing on quality food and excellent service[22]. - The board consists of three independent non-executive directors, accounting for over one-third of the board, ensuring compliance with listing rules[29]. - Total remuneration for independent non-executive directors in 2023 amounted to HKD 531,000, compared to HKD 618,000 in 2022, reflecting a decrease of approximately 14.1%[41]. - The company has adopted a board diversity policy to maintain sustainable development and competitive advantage[54]. - The company has established measurable targets for implementing its board diversity policy, which have been met[55]. - The company recognizes the importance of diverse expertise among board members, including accounting, compliance, and risk management[51]. - The company has established a communication policy to maintain ongoing dialogue with shareholders and stakeholders, encouraging their participation and feedback[129]. - The company’s governance committee includes one executive director and two independent non-executive directors, ensuring compliance with corporate governance policies[121]. - The company’s board has adopted a remuneration policy for directors and senior management, linking compensation to performance metrics[120]. Risk Management - The board of directors is responsible for overseeing the overall risk management procedures, integrating risk management into business processes[116]. - The company has established a risk management framework based on the COSO model, identifying key risks and implementing control measures to mitigate them[135]. - The internal audit department has reviewed the effectiveness of the risk management and internal control systems, finding them to be effective and sufficient[136]. - The company has identified significant financial risks, including liquidity issues and the inability to renew bank loans on time, and is actively working to address these[158]. Shareholder Relations - The group maintains communication with shareholders through annual and interim reports, investor meetings, and a dedicated website for updates on business operations and financial performance[110]. - The annual general meeting for 2024 is scheduled for June 20, 2024, to approve the audited consolidated financial statements for 2023 and other matters[115]. - The company has amended its articles of association to allow for electronic or hybrid meetings for shareholder meetings[167]. - The company has adopted a dividend policy aimed at providing stable and sustainable returns to shareholders, with the actual dividend amount to be determined at the board's discretion based on various factors[132]. - The company has adopted a dividend policy, but the board does not recommend any dividend distribution for the current year[173]. - The company aims to maintain a dividend policy of at least 15% of annual profit attributable to equity holders in the foreseeable future[153]. Strategic Initiatives - Export sales, settled in USD, accounted for approximately 25.8% of the group's revenue for the year, compared to none in 2022, reflecting a diversification in revenue sources[6]. - The group is actively participating in industry conferences and maintaining close business relationships with major animal feed manufacturers to strengthen its market position[13]. - The company is focusing on enhancing R&D and diversifying its product portfolio to respond to intense market competition in the lysine market[158]. - The company has established strong long-term relationships with major customers and is actively seeking new clients to mitigate risks associated with customer dependency[187]. - Supply chain management is prioritized, with a commitment to selecting quality suppliers and conducting annual performance reviews[188]. - One of the corporate goals is to enhance shareholder value through sustainable business growth[189]. Compliance and Ethics - The company has implemented a culture of compliance with the highest ethical standards and is committed to adhering to all applicable laws and regulations[184]. - The company has established procedures for handling and disclosing inside information in compliance with securities regulations[165]. - The internal audit team reports directly to the audit committee, ensuring unrestricted access to all business units and resources[140]. - The internal audit department conducts audits at least once every three years for major business units, with newly acquired businesses audited within twelve months[163]. - The company has not identified any significant control failures or weaknesses during the annual review of its internal controls and risk management systems[162].